Document Detail


Clinical effects of eplerenone, a selective aldosterone blocker, in Japanese patients with essential hypertension.
MedLine Citation:
PMID:  19865106     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Eplerenone, a selective aldosterone blocker, has become clinically available in Japan since 2007. It has been reported that eplerenone has a potential antihypertensive effect, with a profile slightly different from that of spironolactone, and has fewer adverse reactions, suggesting that it may become a first-line treatment for hypertension. However, clinical data on hypertensive patients in Japan are lacking for eplerenone. In this study, we explored the clinical efficacy of eplerenone when it is added to an angiotensin-converting enzyme (ACE) inhibitor or a long-acting calcium channel blocker (CCB) in 68 (31 males, 37 females) Japanese patients with essential hypertension. After adding 50 mg of eplerenone to their basal treatment, blood pressure was significantly reduced at 4 weeks, and further reduced after 24 weeks of eplerenone treatment. Urinary albumin excretion decreased significantly after 24 weeks. There were no significant differences in general biochemical test values or electrolytes, but fasting serum triglycerides were significantly decreased after eplerenone treatment. The serum potassium level showed no significant change during treatment. There were no significant correlations between plasma renin activity or plasma aldosterone concentration (PAC) before eplerenone treatment and blood pressure after eplerenone treatment, showing that the antihypertensive effect of eplerenone is not affected by the patient's renin profile or pretreatment PAC values. Eplerenone was also effective in hypertensive patients with metabolic syndrome. In conclusion, eplerenone, when coadministered with an ACE inhibitor or a long-acting CCB, caused an extremely beneficial antihypertensive effect in Japanese patients with essential hypertension, without few clinically important adverse events.
Authors:
A Sato; S Fukuda
Related Documents :
11244006 - Arterial pressure, left ventricular mass, and aldosterone in essential hypertension.
11230376 - Aldosterone receptor antagonism normalizes vascular function in liquorice-induced hyper...
12119796 - Pathogenesis and clinical physiology of hypertension.
12422136 - Clinical implications of aldosterone blockade.
15834286 - Stress-induced increases in interleukin-6 and fibrinogen predict ambulatory blood press...
726816 - Differences in the effects of secretin and glucagon on the blood circulation of unanest...
Publication Detail:
Type:  Journal Article     Date:  2009-10-29
Journal Detail:
Title:  Journal of human hypertension     Volume:  24     ISSN:  1476-5527     ISO Abbreviation:  J Hum Hypertens     Publication Date:  2010 Jun 
Date Detail:
Created Date:  2010-05-13     Completed Date:  2010-08-24     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8811625     Medline TA:  J Hum Hypertens     Country:  England    
Other Details:
Languages:  eng     Pagination:  387-94     Citation Subset:  IM    
Affiliation:
Department of Internal Medicine, International University of Health and Welfare Mita Hospital, Tokyo, Japan. atsu-sa@iuhw.ac.jp
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Albuminuria / drug therapy
Aldosterone / blood
Aldosterone Antagonists / therapeutic use*
Angiotensin-Converting Enzyme Inhibitors / therapeutic use
Antihypertensive Agents / therapeutic use
Asian Continental Ancestry Group
Calcium Channel Blockers / therapeutic use
Drug Therapy, Combination
Female
Humans
Hypertension / drug therapy*
Japan
Male
Metabolic Syndrome X / drug therapy
Middle Aged
Renin / blood
Spironolactone / analogs & derivatives*,  therapeutic use
Treatment Outcome
Triglycerides / blood
Chemical
Reg. No./Substance:
0/Aldosterone Antagonists; 0/Angiotensin-Converting Enzyme Inhibitors; 0/Antihypertensive Agents; 0/Calcium Channel Blockers; 0/Triglycerides; 0/eplerenone; 52-01-7/Spironolactone; 52-39-1/Aldosterone; EC 3.4.23.15/Renin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Modulation of serum uric acid levels by inosine in patients with multiple sclerosis does not affect ...
Next Document:  Value of retinal examination in hypertensive encephalopathy.